Skip to main content
SpringerLink
Log in

Management of cytokine release syndrome related to CAR-T cell therapy

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy is a novel cellular immunotherapy that is widely used to treat hematological malignancies, including acute leukemia, lymphoma, and multiple myeloma. Despite its remarkable clinical effects, this therapy has side effects that cannot be underestimated. Cytokine release syndrome (CRS) is one of the most clinically important and potentially life-threatening toxicities. This syndrome is a systemic immune storm that involves the mass cytokines releasing by activated immune cells. This phenomenon causes multisystem damages and sometimes even death. In this study, we reported the management of a patient with recurrent and refractory multiple myeloma and three patients with acute lymphocytic leukemia who suffered CRS during CAR-T treatment. The early application of tocilizumab, an anti-IL-6 receptor antibody, according to toxicity grading and clinical manifestation is recommended especially for patients who suffer continuous hyperpyrexia, hypotensive shock, acute respiratory failure, and whose CRS toxicities deteriorated rapidly. Moreover, low doses of dexamethasone (5–10 mg/day) were used for refractory CRS not responding to tocilizumab. The effective management of the toxicities associated with CRS will bring additional survival opportunities and improve the quality of life for patients with cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol 2015; 36(8): 494–502

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3(4): 388–398

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M. Chimeric antigen receptorengineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010; 2010: 956304

    Article  PubMed  PubMed Central  Google Scholar 

  4. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016; 127(26): 3321–3330

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6(224): 224ra25

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385(9967): 517–528

    Article  Google Scholar 

  7. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371(16): 1507–1517

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124(2): 188–195

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Neelapu SS, Tummala S, Kebriaei P,Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat Rev Clin Oncol 2018; 15(1): 47–62

    Article  CAS  PubMed  Google Scholar 

  10. Hay KA, Hanafi LA, Li D, Gust J, Liles WC. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 2017; 130(21): 2295–2306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7(303): 303ra139

    Article  PubMed  PubMed Central  Google Scholar 

  12. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368(16): 1509–1518

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016; 126(6): 2123–2138

    Article  PubMed  PubMed Central  Google Scholar 

  14. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33(6): 540–549

    Article  CAS  PubMed  Google Scholar 

  15. Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD,Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 2015; 373(11): 1040–1047

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016; 6(6): 664–679

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5(177): 177ra38

    Article  PubMed  PubMed Central  Google Scholar 

  18. Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH. Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin- targeted CAR-T cells. J Immunother 2017; 40(3): 104–107

    Article  CAS  PubMed  Google Scholar 

  19. Brudno JN, Maric I, Hartman SD, Rose JJ,Wang M, Lam N, Stetler-Stevenson M, Salem D, Yuan C, Pavletic S, Kanakry JA, Ali SA, Mikkilineni L, Feldman SA, Stroncek DF, Hansen BG, Lawrence J, Patel R, Hakim F, Gress RE, Kochenderfer JN. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol 2018; 36(22): 2267–2280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, Brudno JN, Stetler-Stevenson M, Feldman SA, Hansen BG, Fellowes VS, Hakim FT, Gress RE, Kochenderfer JN. T cells expressing an anti- B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 2016; 128(13): 1688–1700

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cellinduced severe or life-threatening cytokine release syndrome. Oncologist 2018; 23(8): 943–947

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112(10): 3959–3964

    Article  CAS  PubMed  Google Scholar 

  23. Maus MV, Levine BL. Chimeric antigen receptor T-cell therapy for the community oncologist. Oncologist 2016; 21(5): 608–617

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu TL, Feldman SA, Iwamoto AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuver B, Hakim FT, Rosenberg SA, Gress RE, Kochenderfer JN. Allogeneic T cells that express an anti- CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stemcell transplantation without causing graft-versus-host disease. J Clin Oncol 2016; 34(10): 1112–1121

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010; 18(4): 666–668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119(12): 2709–2720

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014; 20(2): 119–122

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 2014; 26(1): 43–49

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Casucci M, Hawkins RE, Dotti G, Bondanza A. Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol Immunother 2015; 64(1): 123–130

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. These three authors contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710004, China

    Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Wanggang Zhang, Wanhong Zhao & Aili He

  2. Nanjing Legend Biotech Inc., Nanjing, 210000, China

    Xiaohu Fan & Qiuchuan Zhuang

Authors
  1. Hongli Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fangxia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pengyu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yilin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yinxia Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaohu Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xingmei Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jie Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Baiyan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Bo Lei
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Liufang Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ju Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Lili Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Ruili Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Qiuchuan Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Wanggang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Wanhong Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Aili He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wanggang Zhang, Wanhong Zhao or Aili He.

Ethics declarations

Hongli Chen, Fangxia Wang, Pengyu Zhang, Yilin Zhang, Yinxia Chen, Xiaohu Fan, Xingmei Cao, Jie Liu, Yun Yang, Baiyan Wang, Bo Lei, Liufang Gu, Ju Bai, Lili Wei, Ruili Zhang, Qiuchuan Zhuang, Wanggang Zhang, Wanhong Zhao, and Aili He declare no competing interests. The clinical trials of LCAR-B38M therapy and CD19-CAR-T cells therapy were approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, H., Wang, F., Zhang, P. et al. Management of cytokine release syndrome related to CAR-T cell therapy. Front. Med. 13, 610–617 (2019). https://doi.org/10.1007/s11684-019-0714-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-019-0714-8

Keywords

Search

Navigation